Q32 Bio Inc
QTTB1.850USD
+0.110+6.32%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
22.57MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Q32 Bio Inc Unternehmen
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
Unternehmensinformationen
BörsenkürzelQTTB
Name des UnternehmensQ32 Bio Inc
IPO-datumMar 28, 2018
CEOMs. Jodie Pope Morrison
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeMar 28
Addresse830 Winter Street
StadtWALTHAM
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02451
Telefon17819990232
Websitehttps://www.q32bio.com/
BörsenkürzelQTTB
IPO-datumMar 28, 2018
CEOMs. Jodie Pope Morrison
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Umsatzaufteilung
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.85%
Andere
43.90%
Aktionäre
Aktionäre
Anteil
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.85%
Andere
43.90%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
28.82%
Private Equity
18.47%
Investment Advisor
17.33%
Corporation
5.92%
Hedge Fund
1.98%
Investment Advisor/Hedge Fund
1.76%
Research Firm
1.17%
Individual Investor
0.62%
Andere
23.93%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
211
9.72M
79.73%
-4.89M
2025Q1
223
10.26M
84.16%
-4.38M
2024Q4
223
11.35M
93.20%
-1.04M
2024Q3
208
11.60M
102.62%
+2.77M
2024Q2
197
10.02M
90.20%
+1.83M
2024Q1
230
9.37M
85.14%
+7.24M
2023Q4
242
1.68M
52.16%
-377.72K
2023Q3
262
1.62M
50.50%
-460.61K
2023Q2
275
1.63M
50.84%
-543.11K
2023Q1
291
1.72M
53.55%
-518.81K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
OrbiMed Advisors, LLC
2.25M
18.47%
--
--
Mar 31, 2025
Atlas Venture
2.09M
17.15%
--
--
Mar 31, 2025
Abingworth Management Limited
1.10M
9.04%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
803.42K
6.59%
--
--
Mar 31, 2025
Monaco asset management S.A.M.
505.45K
4.14%
-69.36K
-12.07%
Mar 31, 2025
ARCH Venture Partners
320.48K
2.63%
--
--
Mar 31, 2025
Pfizer Inc
277.78K
2.28%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
309.21K
2.54%
-7.36K
-2.32%
Mar 31, 2025
Sanofi SA
244.08K
2%
--
--
Mar 31, 2025
Bristol Myers Squibb
200.24K
1.64%
-558.90K
-73.62%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Datum
Art
Verhältnis
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
